Cooley advised Akeso, Inc. on the offering. Akeso, Inc. (Hong Kong Exchange code: 9926.HK), a commercial-stage biopharmaceutical company, announced its HK$1.2 billion (appr. USD$153.29 million) follow-on public...
You must be a Standard 1 Year member to access this content.
Cooley, Jingtian & Gongcheng and King & Wood Mallesons advised YZY Biopharma, while Sidley and Merits & Tree acted as legal counsel for the sole sponsor...
You must be a Standard 1 Year member to access this content.
Cooley and JunHe advised ImmuneOnco Biopharmaceuticals on the offering, and Kirkland & Ellis and Jingtian & Gongcheng advised the joint sponsors and underwriters. ImmuneOnco Biopharmaceuticals announced...
You must be a Standard 1 Year member to access this content.
Davis Polk, Jingtian & Gongcheng and Harney Westwood advised Laekna, while Cooley and Commerce & Finance Law Offices advised the sole sponsor and the underwriters. Laekna,...
You must be a Standard 1 Year member to access this content.
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
You must be a Standard 1 Year member to access this content.
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
You must be a Standard 1 Year member to access this content.
Cooley advised the joint sponsors and underwriters on the deal while O’Melveny represented Cryofocus Medtech (Shanghai) Co., Ltd. Cryofocus Medtech announced its HK$210 million ($27 million) initial...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP advised the underwriters in the transaction while Cooley and JunHe represented Asymchem Laboratories. Asymchem Laboratories (Tianjin) Co., Ltd (Asymchem), a leading drug...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers and Cooley LLP advised Keymed Biosciences Inc. on the deal, while Kirkland & Ellis advised the joint sponsors and underwriters. Keymed Biosciences Inc....
You must be a Standard 1 Year member to access this content.
